CYP2C19 Polymorphism
6
3
3
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
33%
2 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Implementation of Onsite Rapid CYP2C19 Assay for Genotype Guided Dual Antiplatelet Therapy After Acute Ischemic Stroke
POPular GUILTY PILOT: Genotype-guided Clopidogrel Monotherapy
CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention
The Influence of Gene Polymorphism on Clinical Outcomes in Patients Undergoing PCI
Clinical and Genetic Influencing Factors on Clozapine Pharmacokinetics
Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication